Natera stock trades at USD 396.98 as clinical trials expand

Published on 10/07/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock traded at USD 396.98 on October 7, 2026, while the market value stood at USD 56.9 billion. Q2 revenue rose 37.7 percent to USD 752.8 million.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) carried a market capitalization of USD 56.9 billion on October 7, 2026, while NTRA was trading at USD 396.98 on Nasdaq at 11:10 a.m. ET. The quote was down USD 3.67, or 0.92 percent, from the prior close of USD 400.65.

Trials add pipeline depth

Business Wire reported on October 7, 2026, that Natera had enrolled the first patients in a Signatera-guided melanoma study sponsored by NYU Langone Health. The trial is designed to use molecular residual disease testing to guide treatment escalation for advanced or metastatic melanoma, with progression-free survival as its primary endpoint.

A separate breast cancer program expands the commercial and clinical scope of the platform. In a release dated October 5, 2026, Natera said AFT-70 NAVIGATE would enroll more than 2,000 patients at approximately 200 sites. The phase III study pairs Signatera monitoring with giredestrant and tests whether treatment intensity can be adjusted according to residual disease.

Revenue growth meets valuation

Natera's second-quarter 2026 revenue rose 37.7 percent year over year to USD 752.8 million, while oncology test volume increased 57.2 percent, according to QuiverQuant. Management raised 2026 revenue guidance to USD 2.85 billion to USD 2.91 billion from USD 2.74 billion to USD 2.82 billion, a USD 100 million increase at the midpoint.

The growth figures provide the operating counterweight to the valuation. Natera reported a second-quarter loss of USD 0.47 per share against a USD 0.49 consensus loss, while the net loss narrowed to USD 67.0 million from USD 101.7 million in the year-ago quarter, as reported by QuiverQuant.

Citi target sits above market

The analyst backdrop remains more ambitious than the current quote. Markets Insider reported on October 6, 2026, that Citi raised its Natera price target to USD 480 from USD 365 and retained a Buy rating after meeting with management. The USD 480 target lies 20.91 percent above the USD 396.98 Nasdaq price.

Stock stays below yearly peak

NTRA traded between USD 383.45 and USD 399.18 on October 7, 2026, with volume of 1,538,736 shares. The price was 9.24 percent below the 52-week high of USD 437.41 and 136.32 percent above the 52-week low of USD 167.99.